At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 460 enrolled
Drug / intervention
Rivoceranib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer
In Brief
A Phase 3 clinical trial evaluating Rivoceranib and Placebo for Gastric Cancer and Gastric Adenocarcinoma. Completed, enrolled 460 participants across 95 sites in 12 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Gastric Adenocarcinoma
CountriesFrance, Germany, Italy, Japan, Poland, Romania, Russia, South Korea, Taiwan, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMar 2017
Primary CompletionFeb 2019
Study CompletionSep 2020
TodayJul 2026
First PostedFeb 3, 2017
Enrollment StartMar 14, 2017
Primary CompletionFeb 15, 2019
Study CompletionSep 23, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.4 years ago
Interventions
Rivoceranibdrug
Oral tablet
Placebodrug
Oral tablet